Bihua Chen - Aug 1, 2025 Form 4 Insider Report for Biomea Fusion, Inc. (BMEA)

Signature
/s/ Bihua Chen
Stock symbol
BMEA
Transactions as of
Aug 1, 2025
Transactions value $
$0
Form type
4
Date filed
8/1/2025, 04:05 PM
Previous filing
Jun 13, 2025
Next filing
Aug 13, 2025

Reporting Owners (4)

Name Relationship Address Signature Signature date CIK
Chen Bihua Former Director C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON /s/ Bihua Chen 2025-08-01 0001599214
Cormorant Global Healthcare Master Fund, LP Former 10% Holder 200 CLARENDON STREET, 52ND FLOOR, BOSTON /s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP, By: Cormorant Global Healthcare GP, LLC, its General Partner By: Bihua Chen, Managing Member 2025-08-01 0001618442
Cormorant Private Healthcare Fund III LP Former 10% Holder 200 CLARENDON STREET, 52ND FLOOR, BOSTON /s/ CORMORANT PRIVATE HEALTHCARE FUND III, LP By: Cormorant Private Healthcare GP III, LLC, its General Partner By: Bihua Chen, Managing Member 2025-08-01 0001817320
Cormorant Asset Management, LP Former 10% Holder 200 CLARENDON STREET, 52ND FLOOR, BOSTON /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner, By: Bihua Chen, Managing Member 2025-08-01 0001583977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BMEA Common Stock 3.57M Aug 1, 2025 See Footnotes F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BMEA Stock Option (right to buy) 28.9K Aug 1, 2025 Common Stock 28.9K $17.00 Direct F3, F4
holding BMEA Stock Option (right to buy) 23.9K Aug 1, 2025 Common Stock 23.9K $10.20 Direct F4, F5
holding BMEA Stock Option (right to buy) 6.99K Aug 1, 2025 Common Stock 6.99K $38.90 Direct F4, F5
holding BMEA Stock Option (right to buy) 51K Aug 1, 2025 Common Stock 51K $4.63 Direct F4, F5
holding BMEA Stock Option (Right to Buy) 92K Aug 1, 2025 Common Stock 92K $2.50 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Bihua Chen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F2 Represents (i) 1,795,928 shares of Common Stock held by the Master Fund, (ii) 1,717,232 shares of Common Stock held by Fund III, and (iii) 57,712 shares of Common Stock held by the Account.
F3 The options were granted with a 36 month vesting period, vesting monthly.
F4 Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.
F5 The options vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to Ms. Chen's continuing service to the Issuer through such vesting date.

Remarks:

Bihua Chen resigned as a director of the Issuer as of July 22, 2025. As a result, and in light of the fact that none of the reporting persons beneficially owns over 10% of the outstanding shares of Common Stock of the Issuer, the reporting persons no longer intend to report transactions in such securities on Form 4 or Form 5.